Anupam Rama
Stock Analyst at JP Morgan
(3.29)
# 1,031
Out of 4,918 analysts
263
Total ratings
42.66%
Success rate
3.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Neutral | $140 → $145 | $128.91 | +12.48% | 18 | Jul 31, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Neutral | $14 | $10.74 | +30.35% | 8 | Jul 30, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Neutral | $24 | $15.91 | +50.85% | 17 | Jul 29, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Overweight | $66 → $72 | $24.26 | +196.78% | 9 | Jul 28, 2025 | |
| ANAB AnaptysBio | Maintains: Overweight | $42 → $80 | $24.67 | +224.28% | 12 | Jul 24, 2025 | |
| REPL Replimune Group | Downgrades: Neutral | $19 → $9 | $7.60 | +18.42% | 10 | Jul 22, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $25 → $29 | $11.40 | +154.39% | 6 | Jul 10, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $30 → $28 | $5.33 | +425.33% | 4 | Mar 28, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $104 → $117 | $28.44 | +311.39% | 3 | Mar 27, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $44 → $50 | $47.37 | +5.55% | 9 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $9.98 | +310.82% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $36.83 | +38.47% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $11 | $6.83 | +61.05% | 7 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $6.65 | +411.66% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $77 → $71 | $20.96 | +238.74% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $54 | $22.95 | +135.29% | 16 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $15.58 | +182.50% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $22 | $10.13 | +117.28% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $14.90 | +101.41% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $6.32 | +169.20% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $31.98 | +25.08% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $77.76 | +60.75% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.82 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.54 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.35 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.46 | +428.46% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $4.21 | +2,037.77% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.65 | - | 6 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $11.55 | +2,064.50% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.74 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $36.69 | +58.08% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $10.91 | +9.99% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $5.03 | +636.32% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $53.83 | +2.17% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.39 | +1,921.66% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $35.05 | +54.07% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.33 | +13,536.36% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $10.05 | +168.66% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.10 | +296.24% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $401.80 | -65.90% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $4.53 | +760.93% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $6.06 | +692.08% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.86 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.38 | +4,603.42% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.87 | +3,348.28% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $52.13 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.77 | - | 2 | Jul 21, 2017 |
Neurocrine Biosciences
Jul 31, 2025
Maintains: Neutral
Price Target: $140 → $145
Current: $128.91
Upside: +12.48%
RAPT Therapeutics
Jul 30, 2025
Upgrades: Neutral
Price Target: $14
Current: $10.74
Upside: +30.35%
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $15.91
Upside: +50.85%
IDEAYA Biosciences
Jul 28, 2025
Maintains: Overweight
Price Target: $66 → $72
Current: $24.26
Upside: +196.78%
AnaptysBio
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $24.67
Upside: +224.28%
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $9
Current: $7.60
Upside: +18.42%
Cogent Biosciences
Jul 10, 2025
Maintains: Overweight
Price Target: $25 → $29
Current: $11.40
Upside: +154.39%
Olema Pharmaceuticals
Mar 28, 2025
Maintains: Overweight
Price Target: $30 → $28
Current: $5.33
Upside: +425.33%
Ultragenyx Pharmaceutical
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $28.44
Upside: +311.39%
BridgeBio Pharma
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $47.37
Upside: +5.55%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $9.98
Upside: +310.82%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $36.83
Upside: +38.47%
Mar 13, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $6.83
Upside: +61.05%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $6.65
Upside: +411.66%
Mar 4, 2025
Maintains: Overweight
Price Target: $77 → $71
Current: $20.96
Upside: +238.74%
Mar 4, 2025
Maintains: Overweight
Price Target: $50 → $54
Current: $22.95
Upside: +135.29%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $15.58
Upside: +182.50%
Feb 26, 2025
Maintains: Overweight
Price Target: $21 → $22
Current: $10.13
Upside: +117.28%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $14.90
Upside: +101.41%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $6.32
Upside: +169.20%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $31.98
Upside: +25.08%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $77.76
Upside: +60.75%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.82
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.54
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.46
Upside: +428.46%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $4.21
Upside: +2,037.77%
Jul 25, 2023
Downgrades: Underweight
Price Target: n/a
Current: $6.65
Upside: -
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $11.55
Upside: +2,064.50%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.74
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $36.69
Upside: +58.08%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $10.91
Upside: +9.99%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $5.03
Upside: +636.32%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $53.83
Upside: +2.17%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.39
Upside: +1,921.66%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $35.05
Upside: +54.07%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.33
Upside: +13,536.36%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $10.05
Upside: +168.66%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.10
Upside: +296.24%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $401.80
Upside: -65.90%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $4.53
Upside: +760.93%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $6.06
Upside: +692.08%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.86
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.38
Upside: +4,603.42%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.87
Upside: +3,348.28%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $52.13
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.77
Upside: -